Edition:
United States

Cocrystal Pharma Inc (COCP.OQ)

COCP.OQ on NASDAQ Stock Exchange Capital Market

1.88USD
18 May 2018
Change (% chg)

$-0.01 (-0.53%)
Prev Close
$1.89
Open
$1.87
Day's High
$1.88
Day's Low
$1.85
Volume
4,996
Avg. Vol
--
52-wk High
$6.43
52-wk Low
$1.61

Chart for

About

Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a... (more)
No analyst recommendations are available for .

Overall

Beta: 1.93
Market Cap(Mil.): $178.00
Shares Outstanding(Mil.): 726.53
Dividend: --
Yield (%): --

Financials

  COCP.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.10 -- --
ROI: -41.96 14.84 14.38
ROE: -52.95 16.34 16.07

BRIEF-Cocrystal Pharma Posts Qtrly Net Loss Of About $1.6 Mln

* COCRYSTAL PHARMA REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 11 2018

BRIEF-Cocrystal Pharma Prices $8,000,000 Common Stock Offering

* COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING

May 01 2018

BRIEF-Cocrystal Pharma Receives FDA Clearance To Initiate Phase 2A Clinical Study Evaluating CC 31244 For Treatment Of Hepatitis C Virus

* 31244 WITH APPROVED HCV DRUGS Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-Cocrystal Pharma Provides Corporate Overview

* COCRYSTAL PHARMA REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE OVERVIEW AND BUSINESS OUTLOOK

Mar 22 2018

BRIEF-Cocrystal Pharma Files For Non Timely 10-K

* COCRYSTAL PHARMA INC FILES FOR NON TIMELY 10-K - SEC FILING‍​ Source text - http://bit.ly/2FMME8d Further company coverage:

Mar 19 2018

Earnings vs. Estimates

No consensus analysis data available.